1 / 18

Malaria Vaccines: What we need for success

Malaria Vaccines: What we need for success. Christian Loucq, MD Director, PATH Malaria Vaccine Initiative 8 July 2008 UK All-Party Parliamentary Malaria Group. Why I’m Here: To Answer Three Questions. What is the PATH Malaria Vaccine Initiative (MVI)? Why a vaccine? What will it take?.

ruthmbrown
Download Presentation

Malaria Vaccines: What we need for success

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Malaria Vaccines:What we need for success Christian Loucq, MD Director, PATH Malaria Vaccine Initiative 8 July 2008 UK All-Party Parliamentary Malaria Group

  2. Why I’m Here: To Answer Three Questions • What is the PATH Malaria Vaccine Initiative (MVI)? • Why a vaccine? • What will it take?

  3. To accelerate the development of malaria vaccines and ensuretheir availability and accessibility in the developing world A world free from malaria Founded in 1999 Donors: Bill & Melinda Gates FoundationUS Agency for International Development, ExxonMobil, private individuals

  4. To accelerate the development of malaria vaccines and ensuretheir availability and accessibility in the developing world • Availability: • Global access • Regulatory & policy pathways • Accessibility: • Preparing countries for the vaccine introduction • Decision-making framework A world free from malaria

  5. MVI: A global programof PATH

  6. Why a Malaria Vaccine?

  7. Why a Malaria Vaccine?Age Distribution of Severe Malaria Sukuta Kalifi N Kalifi S Siaya Gupta et al., Nature Medicine 5: 340-342, 1999 0.14 0.12 0.1 0.08 0.06 0.04 0.02 0 Proportion Affected 1-2 mos 3-4 mos 5-6 mos 6-12 mos 1 2 3 4 5 6 7 8 9 Age group

  8. Targeting the Parasite Lifecycle

  9. Research and Development Strategy

  10. Phase 2b Phase 1b Phase 1a Phase 1/2a Final Formulation Toxicology Process Development Construct Selection Sanaria PfSPZ GSK RTS,S AS01/AS02 Product Candidates Targets P. vivax Pre-erythroctyic (liver) Pre-erythroctyic (liver) ICGEB/BBIL PvRII LaTrobe MSP2 ISA720 Monash MSP4 GenVec Ad5-CSP: LSA1:Ag2 + Ad5-MSP1: AMA1 Blood-stage MVDB AMA1-C1 ISA720 Research Programs Adjuvanted Recombinant Proteins Viral Vectored Live Attenuated (weakened) WRAIR/GSK AMA1 AS01/AS02

  11. RTS,S Clinical Research Center Network IRSS - Centre Muraz KHRC, Kintampo KCCR, Kumasi KEMRI - Kisumu HAS, Lambarene KEMRI - Kilifi JMP, Korogwe IHDRC, Bagamoyo KCH, Lilongwe CISM, Manhiça RTS,S MVI-GSK Program in Africa

  12. WHO Vaccine PrioritizationVaccines that may be licensed by 2012(WHO SAGE, November 2007) Weighted priority score based upon expert opinion

  13. Sanaria: A Different Approach • Targets the whole parasite • Uses a live, attenuated parasite

  14. Challenges: What will it take? • No vaccine against a parasite • No known correlates of immunity • No “market”

  15. What will it take? Strong partners

  16. What will it take? Sustained commitment

  17. Partners Today … and Tomorrow

  18. What can you do? • Support investments in malaria control today • Advocate now for investments in the tools for tomorrow • And …

More Related